Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds.

Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds.

Item
http://www.wikidata.org/entity/Q33359104
Rational methods for the selection of diverse screening compoundsComputational prediction and validation of an expert's evaluation of chemical probesAnalysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Cheminformatics aspects of high throughput screening: from robots to models: symposium summaryHigh-throughput screen of natural product libraries for hsp90 inhibitors.Wine Compounds as a Source for HTS Screening Collections. A Feasibility Study.Serendipity in anticancer drug discoverySize estimation of chemical space: how big is it?In Silico ADME/Tox PredictionsVirtual screening for novel Atg5–Atg16 complex inhibitors for autophagy modulation
P2860

Investigation of the incidence of "undesirable" molecular moieties for high-throughput screening compound libraries in marketed drug compounds.

Item
http://www.wikidata.org/entity/Q33359104
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Investigation of the incidence ...... es in marketed drug compounds.
@ast
Investigation of the incidence ...... es in marketed drug compounds.
@en
type
label
Investigation of the incidence ...... es in marketed drug compounds.
@ast
Investigation of the incidence ...... es in marketed drug compounds.
@en
prefLabel
Investigation of the incidence ...... es in marketed drug compounds.
@ast
Investigation of the incidence ...... es in marketed drug compounds.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Investigation of the incidence ...... es in marketed drug compounds.
@en
P2093
P304
P31
P356
10.1016/J.EJMECH.2008.06.013
P433
P478
P577
P698
P921